EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies

Rebeca Estevez Barcia, Cristóbal Colón iD, Álvaro Hermida-Ameijeiras iD, Laura López-Valverde iD, Daniel Rodrigues, Cristina Domínguez-González iD, Jordi Díaz-Manera iD, Maria L Couce iD, José Victor Alvarez iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27135726 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Rebeca Estevez Barcia und 8 weiteren Autor:innen. Beteiligte Einrichtung: IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Enzyme Replacement Therapy, alpha-Glucosidases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scholarship Galician Innovation Agency-GAIN, MPS-Lysosomal Families Association, “Instituto de Salud Carlos III”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pompe disease (PD) is a rare, autosomal recessive neuromuscular disorder caused by mutations in the gene encoding acid alpha-glucosidase (GAA). The resulting deficiency in GAA, a lysosomal enzyme, leads to the pathological accumulation of glycogen, primarily in cardiac and skeletal muscles. PD presents as a clinical continuum spanning two major phenotypes: infantile-onset Pompe disease (IOPD), the most severe form, typically characterized by onset before 12 months of age, rapid hypertrophic cardiomyopathy, and severe hypotonia; and late-onset Pompe disease (LOPD), which manifests between 12 months of age and adulthood, and is characterized by progressive axial and proximal muscle weakness and respiratory insufficiency. Enzyme replacement therapy (ERT), available since 2006, has improved survival, particularly in IOPD, but is limited by variable efficacy and limited penetration of the blood–brain barrier, necessitating new approaches. In this comprehensive review, we focus on advances in the understanding and management of PD. First, we explore recent diagnostic advances and the characterization of multisystem involvement in PD. Next, we critically discuss the advantages and limitations of current ERT approaches, and advances achieved with next-generation ERT (avalglucosidase alfa, cipaglucosidase alfa + miglustat). Finally, we summarize cutting-edge, potentially curative strategies, including substrate reduction therapy and novel experimental therapies (e.g., gene therapy) that seek to circumvent the limitations of ERT, provide durable effects, and potentially penetrate the central nervous system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIEnzyme Replacement Therapyalpha-GlucosidasesHumansMutation

Stichwörter der Autor:innen

acid alpha-glucosidase deficiencyenzyme replacement therapyinfantile-onset Pompe diseasenewborn screeningurinary glucose tetrasaccharide

Substanzen

alpha-Glucosidases

Autor:innen und Institutionen

  • IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Metabolic Unit, Clinical University Hospital of Santiago de Compostela, CIBERER, MetabERN, RICORS, 15706 Santiago de Compostela, Spain.
  • Department of Forensic Sciences, Pathology, Gynecology and Obstetrics, Pediatrics, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Neuromuscular Unit, Department of Neurology, Research Institute Imas12, Biomedical Network Research Centre on Rare Diseases (CIBERER), Hospital Universitario 12 de Octubre, Instituto de Salud Carlos III, 28041 Madrid, S…
  • The John Walton Muscular Dystrophy Research Center, Newcastle University, Newcastle Upon Tyne NHS Trust, Newcastle upon Tyne NE1 3BZ, UK.
  • Neuromuscular Disorders Laboratory, Insitut de Recerca de l'Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

ORCID-Profile: Cristóbal Colón, Álvaro Hermida-Ameijeiras, Laura López-Valverde, Cristina Domínguez-González, Jordi Díaz-Manera, Maria L Couce, José Victor Alvarez

Förderung

  • Scholarship Galician Innovation Agency-GAIN
  • MPS-Lysosomal Families Association
  • “Instituto de Salud Carlos III”

Zitieren

APA

Estevez Barcia, R., Colón, C., Hermida-Ameijeiras, Á., López-Valverde, L., Rodrigues, D., Domínguez-González, C., Díaz-Manera, J., Couce, M. L., & Alvarez, J. V. (2026). A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135726

Vancouver

Estevez Barcia R, Colón C, Hermida-Ameijeiras Á, López-Valverde L, Rodrigues D, Domínguez-González C, et al. A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27135726

BibTeX
@article{EstevezBarcia2026,
  author = {Estevez Barcia, Rebeca and Colón, Cristóbal and Hermida-Ameijeiras, Álvaro and López-Valverde, Laura and Rodrigues, Daniel and Domínguez-González, Cristina and Díaz-Manera, Jordi and Couce, Maria L and Alvarez, José Victor},
  title = {A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27135726}
}
Kostenlos starten →